The Top Three Age Reversal And Age Extension Stocks

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.


The baby boomers are getting older, and as they age, they become more concerned about their health, living as long as they can, and living as healthy as they can. The boomers get concerned about age related illnesses and diseases that can affect them.

Fortunately, there are a few companies involved in targeting human aging and degenerative diseases. There are many companies involved in developing treatments and cures for many diseases, such as cancer, and may have a small part of their business involved in age reversal. But there aren’t many companies involved age extension as a pure play. Here are a few longevity stocks worth doing further research on.

Cohbar (CWBR) is a clinical stage biotechnology company which concentrates  on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. CohBars therapeutics offer the potential to treat a broad range of diseases, including nonalcoholic steatohepatitis, obesity, fibrotic diseases, cancer, acute respiratory distress syndrome, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company is even in a pre-clinical program for COVID-19 associated ARDS. This  Menlo Park, California based company was founded in 2007. The stock has a market cap of $97 million and has been generating negative earnings. It has $12.5 million in total cash and long term debt of $3.4 million.

AgeX Therapeutics, Inc. (AGE) is an Alameda, California based biotechnology company founded in 2017, with a great stock ticker symbol.The company develops and commercializes novel therapeutics targeting human aging. The company’s two major proprietary technologies are PureStem® and induced Tissue Regeneration (iTR™). PureStem® can generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is the company’s longevity platform with a goal of unlocking cellular immortality and regenerative capacity to reverse age-related changes in the body. The stock has a market cap of $32 million and has been generating negative earnings. It has $2.3 million in total cash and $1.5 million in long term debt.

resTORbio, Inc. (TORC) is a Boston, Massachusetts based company founded in 2016, which is involved in developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. The company’s lead clinical program is selectively targeting TORC1, an evolutionary conserved pathway that contributes to the age-related decline in function of multiple organ systems, including neurologic function. Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases. The stock has a market cap of $77 million and has been generating negative earnings. It has total cash of $91 million and virtually no long term debt.

Please be aware that these are extremely low cap stocks and should be considered very speculative.

Disclosure: Author owns CWBR.

Disclaimer: This article is designed to provide information. It is provided with the understanding that neither the author nor the publisher is engaged ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Adam Reynolds 2 years ago Member's comment

I'm bullish on $TORC. I think it will be at $10 in about a year's time.

Fred Fuld 2 years ago Author's comment

It is an interesting company. I will continue to follow it.

Dean Gilmore 2 years ago Member's comment

Thanks. Interesting mix of small caps summarized.

Fred Fuld 2 years ago Author's comment

Thanks for you feedback.

Derek Snyder 2 years ago Member's comment

$UBX should be on the list - it's the furthest ahead in terms of trials - P2 results due soon. Bezos/Thiel have invested in it, and this is its potential.

Aging biotech is the future of medicine, I have no doubt in my mind about this - you should spend good time researching why - DM me if u need some sources :)

Would also add $LCTX, their recent dry AMD results are simply mindblowing - they managed to regenerate human CNS tissue (retina) and reverse vision loss.

Fred Fuld 2 years ago Author's comment

Thanks for your suggestions. I will include them in future age extension articles.

Derek Snyder 2 years ago Member's comment

Much appreciated Fred!